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Abstract  
Background 
A significant number of patients with major depressive disorder (MDD) have treatment 
resistant depression (TRD), defined as failure to respond adequately to two 
consecutive courses of antidepressants. A Cochrane review suggested that anti-
glucocorticoid augmentation of antidepressants may be effective in TRD. The 
Antiglucocorticoid augmentation of anti-Depressants in Depression (ADD Study) was 
a multicentre two-arm double-blind, patient randomised, placebo controlled trial of the 
cortisol synthesis inhibitor, metyrapone, for augmentation of serotonergic 
antidepressants in patients with TRD in a UK setting. 
Methods 
A randomised double-blind parallel-group trial of metyrapone 500mg twice daily versus 
placebo for three weeks, added to on-going antidepressants, in patients aged 18-65 
with TRD. On-line computer-generated random allocation was stratified for centre and 
primary or secondary care setting. The primary outcome was improvement in 
Montgomery-Åsberg Depression Rating Scale (MADRS) score five weeks after 
randomisation using intention-to-treat analysis. Secondary outcomes included change 
in MADRS in patients with confirmed adherence to metyrapone versus those 
randomised to placebo, effects of metyrapone treatment on anxiety and quality of life 
measures, the persistence of treatment effects up to 6 months and the safety and 
tolerability of metyrapone. Trial registration ISRCTN45338259. 
Findings 
From March 2011 to December 2012, 165 patients were recruited with 86.7% reaching 
primary outcome time point and 63.0% the final 6 months’ assessment. At 5 weeks 
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there was no significant difference between groups on the primary outcome measure, 
MADRS improvement (estimated mean difference -0.51, 95% CI: -3.48, 2.46; p>0.1), 
or on any secondary outcome measures including Beck Depression Inventory, Clinical 
Anxiety Scale, State-Trait Anxiety Inventory or EQ-5D-3L Quality of Life. Similarly 
there were no significant differences in outcomes at any other time points. Restricting 
analysis to metyrapone treated patients with endocrinological evidence of medication 
adherence did not alter the findings. Metyrapone was well tolerated. 
Interpretation 
Metyrapone augmentation of antidepressants is not efficacious in a broadly 
representative population of patients with TRD within the UK National Health Service 
(NHS).  
Funding  
Efficacy and Mechanism Evaluation (EME) programme, which is a UK Medical 
Research Council and National Institute for Health Research partnership. 
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Introduction 
Clinical guidelines recommend the use of antidepressant medication for the treatment 
of moderate to severe major depressive disorder (MDD).1;2 However a significant 
proportion of patients fail to obtain an optimal outcome to both first and second line 
treatments, commonly described as treatment resistant depression (TRD).3;4 
Hypothalamic-Pituitary-Adrenal (HPA) axis abnormalities are often demonstrated in 
patients with mood disorders and there is increasing evidence that such dysregulation 
is associated with poor prognosis, defined both by non-response to antidepressants 
and by an increased likelihood of future relapse.5;6 A Cochrane review suggested 
efficacy of anti-glucocorticoid augmentation of antidepressants in patients with MDD, 
with the largest effect size seen with metyrapone,7 a cortisol synthesis inhibitor. The 
data relating to metyrapone was drawn from a single positive double-blind, placebo 
controlled randomised study of metyrapone (250mg four times daily for 3 weeks) in a 
small sample of 63 depressed inpatients in Germany.8 
 
The primary aim of the “Antiglucocorticoid augmentation of anti-Depressants in 
Depression” (ADD) study was to test the proof-of-concept of metyrapone previously 
established by Jahn and colleagues8 in the most clinically relevant population. The 
ADD study examined the efficacy, tolerability and safety of metyrapone (500mg twice 
a day) for 21 days in augmentation of conventional serotonergic antidepressants in a 
randomised placebo controlled trial (RCT) in patients with MDD who had not 
responded to at least two courses of antidepressants in their current episode (i.e. 
patients with TRD). This is the stage in treatment sequencing at which the current UK 
National Institute for Health and Clinical Excellence (NICE) guidelines for the 
management of depression1 recommend antidepressant augmentation strategies 
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following failure of antidepressant monotherapies. Given that few patients with 
depression are currently admitted to inpatient psychiatric units in the UK,9 the study 
recruited a primarily outpatient (primary and secondary care) UK National Health 
Service (NHS) population. To date, all published studies of the use of anti-
glucocorticoids in patients with TRD have used short treatment periods of 1-3 weeks,7 
which can appear counter-intuitive in such a potentially chronic condition. However, 
evidence suggests that the clinical effects of antiglucocorticoids on HPA axis function 
persist after their administration has ceased.10;11 The persistence of effects on 
depressive symptoms and quality of life was therefore examined in the ADD study at 
21 weeks after stopping metyrapone treatment compared with only 2 weeks’ follow-up 
in the earlier study.8 The hypotheses being tested and the study protocol are published 
elsewhere.12 
 
Methods 
Study Design and Participants 
The ADD study was a multicentre two-arm (1:1 allocation), parallel group, double-
blind, randomised, placebo-controlled superiority trial of augmentation of serotonergic 
antidepressants with metyrapone in patients with moderate to severe MDD who had 
failed to respond to adequate trials of at least two antidepressants in their current 
episode.  
 
The study was conducted in 3 centres recruiting patients from 7 UK NHS Mental Health 
Trusts, and co-localised primary care services, in 3 areas: North East England 
(Northumberland Tyne and Wear NHS Foundation Trust and Tees, Esk and Wear 
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Valleys NHS Foundation Trust); North West England (Manchester Mental Health and 
Social Care NHS Trust, Greater Manchester West Mental Health NHS Foundation 
Trust and Pennine Care NHS Foundation Trust); and the Leeds/Bradford area (Leeds 
and York Partnership NHS Foundation Trust and Bradford District Care NHS 
Foundation Trust). Eligible patients were those aged 18-65 who had a Diagnostic and 
Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV)13 defined major 
depressive episode assessed using the Structured Clinical Interview for DSM (SCID) 
research version.14 They were required to have a Hamilton Depression Rating Scale 
17 item (HDRS17)15 score of ≥18 at both week -2 and 0 relative to randomisation and 
commencement of experimental medication, determined using the GRID-HAMD for 
improved reliability16, a Massachusetts General Hospital Treatment Resistant 
Depression (MGH-TRD) staging score of 2-10 as a measure of treatment resistance17 
and to be on a single agent or combination antidepressant treatment which included 
a serotonergic drug (a selective serotonin reuptake inhibitor, a tertiary amine tricyclic, 
venlafaxine, duloxetine or mirtazapine). At the point of randomisation, patients had to 
have been taking their current antidepressant medication, at the same dose, for a 
minimum of four weeks. Exclusion criteria included: another DSM-IV axis I diagnosis 
(this was later relaxed due to initial slow recruitment to allow patients with an anxiety 
disorder considered to be secondary to a primary diagnosis of depression); physical 
co-morbidity that would make metyrapone inappropriate, including untreated 
hypothyroidism, disorders of steroid production, cardiac failure, angina, myocardial 
infarction in the last 3 years and renal failure; pregnancy or breastfeeding; use of 
medication that would interact with metyrapone; dependence on alcohol or other 
drug(s) in the past 12 months, and/or current harmful use of such substances (defined 
Page | 7 
 
as meeting SCID criteria for harmful use or dependence); current or recent 
participation in a research study that could interfere with results. 
 
A cohort of age and gender matched healthy volunteers (HVs) was recruited to act as 
comparators to the patient cohort in relation to HPA axis function (see below) as well 
as in a range of additional investigations including neurocognitive testing, magnetic 
resonance imaging and electroencephalography which will be reported elsewhere. 
HVs were recruited by advertisements in the University of Manchester and by emails 
sent to the Volunteer Database of the Institute of Neuroscience, Newcastle University. 
HVs were confirmed as having no current or past axis I disorder using DSM-IV criteria 
assessed using the SCID, had no first degree family history of mental illness, and had 
a HDRS17 score of less than 5. Exclusion criteria were the same as for the patient 
cohort. 
 
Randomisation and blinding 
Patients were randomised to metyrapone or placebo using permuted block 
randomisation, stratified by centre (North East, North West or Leeds/Bradford), level 
of care setting (primary or secondary care) and, for the North East and North West 
centres, by whether the patient agreed to participate in the mechanistic studies 
(described elsewhere12). The randomisation code was generated by an independent 
statistician in the Newcastle Clinical Trials Unit with the length of each block randomly 
set at 2 or 4 (with equal probability) unknown to study personnel to ensure 
concealment of allocation. Coded (numbered) packs of study drug and matched 
placebo were produced according to the randomisation schedule, by Catalent Pharma 
Solutions (http://www.catalent.com/index.php). Metyrapone capsules were over-
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encapsulated (using Coni-Snap® capsules, Capsugel, Morristown, N.J, USA.) and 
appeared identical to the placebo capsules, and were dispensed from the clinical trials 
pharmacy at Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle. 
Randomisation was through a centralised web-based system set up by the Newcastle 
Clinical Trials Unit with access to the randomisation code limited to the study 
pharmacist, independent statistician and database manager to ensure concealment of 
allocation. Treatment allocation remained blinded until after the last participant’s final 
24 week visit, apart from an independent examination of unblinded group data by the 
Data Monitoring and Ethics Committee (DMEC) which found no evidence of a 
relationship between those taking metyrapone and suicidal thoughts/attempts.  
 
Procedures 
Patient identification was supported by two hubs of the UK NIHR Mental Health 
Research Network (the North East and North West), a Comprehensive Local 
Research Network (West Yorkshire) and spanned primary and secondary care. A 
schedule of participant visits to study centres and assessments made on these 
occasions is detailed in the Supplementary Table 1 and described elsewhere12, with 
all patients providing written informed consent.   
 
HPA Axis Assessment 
Saliva samples to determine the cortisol awakening response (CAR)18 were obtained 
at week 0 (immediately prior to commencement of treatment augmentation) and then 
at weeks +3 (the day after cessation of experimental medication) and +5. Participants 
collected 5ml of saliva by passive drool19 into a plastic collecting tube on wakening 
and at 15 minute intervals for a further hour. A further sample was collected by the 
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same method at 11pm the night before each of the three CAR assessments. The CAR 
data were analysed by calculating the area under the curve (AUC) of concentration 
against time, calculated using the trapezoidal method with respect to zero (AUCg) and 
with respect to the concentration on waking (AUCi) as previously described.20 
 
In addition serum samples were taken at weeks -2 and +1 for analysis of cortisol 
precursors and metabolites. The increase in 11-deoxycortisol between weeks -2 and 
+1 was used as a measure of adherence to medication since this has been shown to 
be highly sensitive to treatment with metyrapone.8;21 
 
Intervention 
Participants continued their existing antidepressant regime and received study drug 
(metyrapone 500mg or placebo) twice daily, prescribed in the morning and at noon, 
for 21 days (matching previous studies8). All other treatments remained under the 
control of the patient’s usual treating clinician, with encouragement to avoid medication 
changes between enrolment (week -2) and the primary outcome time point (week +5) 
unless there was a compelling clinical reason to do so. Any such changes in treatment 
did not lead to the patient being excluded from analysis. 
 
Outcomes  
The primary outcome measure of mood was the Montgomery-Åsberg Depression 
Rating Scale (MADRS22) which was assessed at week 0 and then at weeks +3 (end 
of active treatment period), +5 (primary outcome time point), +8, +16 and +24 from the 
date medication was started (+/- 2 days). Secondary outcomes included rates of 
response (defined as a 50% or greater reduction in MADRS score) and remission 
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(defined as MADRS ≤ 10) at week+5, the Clinical Anxiety Scale (CAS23), Beck 
Depression Inventory (BDI24), State Trait Anxiety Inventory (STAI25) and Young Mania 
Rating Scale (YMRS26). Quality of life was assessed using the self-completed EQ-5D-
3L instrument (http://www.euroqol.org/)27 and tolerability using the Toronto Side 
Effects Scale (TSES).28 Safety assessments in case of metyrapone induced 
hypocortisolaemia included serum cortisol at week +1 and measurement of sitting and 
standing blood pressure and urea and electrolytes at weeks +1 and +5. 
 
Statistical analysis 
The study was powered to detect a difference with a standardised effect size of d=0.5 
(c.f. that of 0.63 found by Jahn and colleagues8) between groups in the change in 
MADRS scores between baseline and five weeks post-randomisation, requiring 85 
patients per group for 90% power with an alpha of 0.05 (to allow for 10% attrition during 
the trial, the original aim was to randomise 95 per group). Due to slow recruitment, 
and with the agreement of the funder and DMEC, the power requirement was reduced 
to 80% requiring a sample size of 63 per group (70 per group allowing for 10% 
attrition). A full detailed Statistical Analysis Plan (SAP) was agreed with the DMEC 
prior to study completion and breaking of the blind (see Supplementary Material).  
 
The primary outcome was analysed as an intention to treat analysis of covariance of 
MADRS scores at +5 week, covaried for baseline MADRS; strata (centres and whether 
the patient originated in primary or secondary care) and treatment groups were 
included as fixed effects. The persistence of change in MADRS score was assessed 
using repeated measures analysis of variance using data from all time points. 
Secondary outcomes were examined using the same methods. Side effects were 
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assessed using the TSES and YMRS. The YMRS was analysed using the mixed 
models approach described above. For the TSES the relative risk of individual 
symptoms in the two groups was calculated. Pre-specified per-protocol analyses 
according to adherence with medication were carried out, based on measurements of 
11-deoxycortisol prior to randomisation (week -2) and at week +1. A conservative 
criterion was used to judge adherence in the metyrapone group of both the week +1 
11-deoxycortisol concentration, and the increase between week -2 and week +1, being 
greater than the mean plus three times the SD of the placebo group (or week +1 11-
deoxycortisol concentrations more than the placebo mean plus four times the SD of 
the placebo group for subjects missing a week -2 concentration). 
 
The salivary cortisol concentrations at 11pm and the AUCs were non-normally 
distributed and were natural logarithm transformed and compared using paired (for 
changes over time in patients) or non-paired (comparing patients and HVs) t-tests, 
with equal variance not assumed. In the event of data being missing for time points 
used in the AUC analysis, imputation was conducted by inserting the mean of the 
values immediately before and after the missing time point.  Imputation was not used 
for either the first or last data point with subjects being excluded in such circumstances, 
as was the case for subjects with more than one missing data point. 
 
Statistical analysis was conducted using IBM SPSS Statistics for Windows, Version 
20.0 (IBM Corp, Armonk, NY, USA. 2011) and Stata, Version 12 (StataCorp, Texas, 
USA. 2011). The study was registered on 21/12/2009 (ISRCTN45338259) under the 
public title “Antiglucocorticoid augmentation of antiDepressants in Depression: the 
ADD study”. Clinical Trial Authorisation was given by the Medicines and Healthcare 
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products Regulatory Agency (MHRA: EudraCT: 2009-015165-31). Ethical approval 
was granted by the Sunderland Local Research Ethics Committee (REC Ref No. 
10/H0904/9) on 22/04/2010. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, analysis, data 
interpretation, manuscript writing, or decision to submit for publication. The authors 
had full access to all the data. All authors had final responsibility for the decision to 
submit for publication. 
 
Results 
- Figure 1 near here – 
 
The first patient was randomised at the beginning of March 2011 and the last patient 
in mid-December 2012. The last 24 week follow up was in late June 2013 following a 
7 month extension due to initial slow recruitment. The flow of patients through the 
study is detailed in the CONSORT diagram in figure 1. Overall 877 potential patients 
were identified, 237 (27.0%) came from primary care, 320 (36.5%) from secondary 
care and 310 (35.3%) as self-referrals following media exposure of the study or seeing 
posters in GP surgeries (in 10 cases the source of the referral was not clear). Note 
that all self-referrals were currently engaged in treatment within the NHS and were 
subsequently categorised and stratified on the basis of the level of care they were 
receiving (i.e. primary or secondary care). Of these, 284 patients were assessed for 
eligibility by a formal face to face screening. Of the 111 who did not meet inclusion 
criteria, 10 did not meet the criteria for a major depressive episode, 52 had HDRS17 
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item scores < 18, 17 had axis 1 disorders other than anxiety, 9 were on an 
inappropriate antidepressant and 3 had MGH-TRD staging scores outside the range 
of 2-10, 18 had physical disorders which excluded them and 5 had other 
miscellaneous exclusion criteria (3 patients were excluded for more than one reason). 
Eight patients subsequently dropped out before randomisation (i.e. between weeks -
2 and 0), resulting in 165 patients being randomised (82 to placebo and 83 to 
metyrapone), exceeding the revised target and providing an 84% power to detect the 
effects hypothesised in the sample size determinations. Of those randomised, 143 
(86.7%) completed the primary outcome assessments at +5 weeks. Thirty nine 
dropped out between week +5 and week +24 so that 104 (63% of those randomised) 
completed the study. 
 
Overall 42% of patients were recruited from primary care (the proportion differing 
between sites: Newcastle and Durham 69%; Leeds-Bradford 40%; Manchester 14%). 
Baseline data of demographic and clinical characteristics are shown in Table 1. The 
placebo and the metyrapone groups were well balanced on key demographic variables 
and clinical characteristics. In general there were very few missing data items and only 
a small number of missing values needed to be imputed (Supplementary Table 2). 
- Table 1 & Table 2 near here - 
 
Baseline MADRS scores by site and patient origin are shown in Table 2. Scores of 
patients recruited from secondary care were significantly higher than those from 
primary care (mean difference 3.4: 95% CI: 1.5, 5.3). Figure 2 shows the MADRS 
scores of patients in the two treatment groups (metyrapone and placebo) over the 
course of the entire study. Across the two treatment arms considered together there 
Page | 14 
 
was a significant reduction in MADRS scores of 6.0 points (95% CI: 4.5, 7.5) between 
baseline and week +5. However, there was no significant difference between 
treatment groups on the primary outcome (covarying for baseline severity, study 
centre and primary or secondary care location of patients) with an adjusted week +5 
MADRS score difference of 0.51 points (95% CI: -3.48, 2.46). This lack of effect of 
metyrapone was consistent across analyses using all combinations of the three 
covariates – see Supplementary Table 3). Repeated measures analysis of variance 
using data from all assessment time points with the same covariates also found no 
significant difference between treatment arms. Consistent with this, neither response 
nor remission rates were significantly different between treatment groups (Table 3), 
with odds ratios (based on a logistic regression model adjusted for site and origin of 
patient; metyrapone/placebo) of 0.95 (95% CI: 0.41, 2.20) and 0.97 (95% CI: 0.40, 
2.55) for response and remission respectively.   
- Figure 2 and Table 3 near here – 
 
Mean serum 11-deoxycortisol concentrations at week +1 were 0.9 nmol/L (SD=1.4) in 
the placebo group and 36.7 nmol/L (SD=65.9) in the metyrapone group, reflecting a 
1.6 (SD=1.7) and 65.8 (SD=153.8) fold increase respectively compared to week 0. 
Three patients were missing week -2 11-deoxycortisol concentrations and hence had 
adherence judged on the basis of their week +1 concentrations.  All others were judged 
on a combination of week +1 11-deoxycortisol plasma concentration and the increase 
between week -2 and week +1, as described in the methods section. Fifty two patients 
in the metyrapone group (75% of the potential sample) were deemed to be “adherent” 
and were compared with all 74 of the patients in the placebo group. This per-protocol 
analysis found no difference in week +5 MADRS scores co-varying for baseline 
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MADRS score and origin of patient, with the mean difference being -1.65 (95% CI: -
4.94, 1.65). In line with this, there was no difference in response (23.1% vs 21.6%; 
adherent metyrapone vs placebo treated patients) or remission rates (17.3% vs 
16.2%) at week +5 between the two treatment groups. The non-adherent metyrapone 
randomised patients showed a non-significant change in MADRS score from baseline 
to week +5 (-2.94, 95%CI: -6.82, 1.18), while both the adherent metyrapone and 
placebo randomised patients showed a significant reduction (-7.21, 95%CI: -9.60, -
4.79; -5.77, 95%CI: -7.93, -3.66) respectively. 
 
Of the 165 patients randomised, saliva samples were obtained from 151 (92%) for 
measurement of 11pm cortisol concentrations and CAR at week 0. A total of 67 HVs 
age, gender and IQ matched to the patients (see Table 1) were recruited. Saliva 
samples for 11pm cortisol concentrations and CAR data were available for 60 (90%). 
The cortisol data from both the patients and HVs is shown in Figure 3. The 11pm 
cortisol was greater in patients (2.48 nmol/L, SD=4.97) than HVs (1.38 nmol/L, 
SD=1.38; t=2.2, df=132.3, p=0.032 on transformed data). Neither AUCg (patients’ 
untransformed mean=1.36, SD=1.06; HVs’ mean=1.38, SD=0.70; t=0.72, df=209, 
p=0.481) nor AUCi (patients’ mean=0.30, SD=0.73; HVs’ mean=0.23, SD=0.74; 
t=0.64, df=209, p= 0.526) differed between patients and HVs. 
- Figure 3 near here - 
 
Baseline and week +3 11pm and AUC salivary cortisol data were available from 125 
(11pm) and 123 (AUC) patients, 59 (47%, 11pm) and 57 (46%, AUC) of whom were 
randomised to metyrapone. In these latter patients, there was no difference between 
baseline and week +3 11pm cortisol concentration (2.48 nmol/L SD=3.31 vs 3.31 
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nmol/L SD=4.69; t=1.13, df=58, p=0.26), AUCg (mean=1.39, SD=1.2 vs mean=1.41, 
SD=1.07; t=0.10, df=56, p=0.92) or AUCi (mean=0.26, SD=0.86 vs mean=0.27, 
SD=0.65; t=0.99, df=56, p=0.33). 
 
To assess the effect of HPA axis function on response to metyrapone, an analysis of 
the effect of metyrapone on week +5 MADRS scores was conducted covarying for 
baseline 11pm salivary cortisol concentration, AUCg or AUCi, or the difference in 
11pm cortisol concentrations, AUCi or AUCg at week +3 compared to week 0. A lack 
of effect of metyrapone was confirmed in all analyses (for details see Supplementary 
Table 4). 
 
Analysis of secondary outcomes similarly yielded estimated effects of metyrapone that 
were small and not statistically significant, both at the primary outcome time point of 
week +5, and using a repeated measures analysis of variance with all assessment 
time points (see supplementary figures 1-6.  Data regarding all clinical outcome 
measures detailed in Supplementary Table 5). 
 
Twelve serious adverse events were reported for 10 of the patients who were 
randomised to treatment (4 in the metyrapone group and 6 in the placebo group), none 
of which were judged to be related to medication. Most occurred well after the 3-week 
medication period and/or were related to pre-existing conditions (see Supplementary 
Table 6). A total of 229 adverse events were reported, of these 83 (38%; 95% CI: 32%, 
45%) were thought to be possibly related to study medication and 18 (8%; 95% CI: 
4%, 12%) were thought to be definitely related to study medication. Twelve (5%; 95% 
CI: 2%, 9%) of the events led to adjustment, interruption or discontinuation of study 
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medication. One hundred and five of the 165 patients (63.6%; 95% CI: 55.8%, 71.0%) 
had at least one adverse event with the median number of 1 (range: 0-13) and a mean 
of 2.0 (95% CI: 1.6, 2.4). The incidence rate ratios (risk in group randomised to 
metyrapone relative to risk in group randomised to placebo) were: unadjusted estimate 
= 1.34   (95% CI: 0.90, 1.98); estimate adjusted for centre and origin of patient = 1.41 
(95% CI: 0.98, 2.03). Restricting the analysis to events classified as “possibly” or 
“definitely” related to study medication the corresponding estimates are: unadjusted 
estimate = 1.71 (95% CI: 0.98, 3.01); estimate adjusted for centre and origin of patient 
= 1.92 (95% CI: 1.14, 3.24). Similar findings were made with regards to the TSES. 
Across all 32 symptoms rated by this scale, there was no difference between the 
randomised groups in terms of incidence. There were two symptoms where the 
difference was significant at the 5% level (delayed ejaculation and weight loss both 
being greater in the placebo group). No differences were seen in the incidence of CNS 
side effects (for full details of all TSES rated side effects see Supplementary Table 7). 
There was no difference between treatment groups on the YMRS consistent with a 
lack of risk of mania following treatment with metyrapone in this patient population. 
 
There were six instances of hypocortisolaemia during the study (one on placebo and 
5 on metyrapone). In all cases these were asymptomatic based on a Standard 
Operating Procedure for PIs on the management of low cortisol that included 
information on associated symptoms. As part of a Standard Operating Procedure all 
patients with hypocortisolaemia had their lying and standing BP and urea and 
electrolytes checked but no abnormalities were detected in these measures. 
Medication was continued and repeat cortisol measurements at later dates returned 
to normal.  
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The DMEC requested that the risk of events indicating raised levels of suicidality be 
compared between the two trial arms. Using data from the suicide risk assessment 
tool (drawn from the Mini-International Neuropsychiatric Interview29) , the incidence 
rate ratio (metyrapone/placebo) based on a negative binomial regression model 
adjusting for centre and origin of patient care was 0.47 (95% CI: 0.17, 1.32) suggesting 
no evidence of an increased risk of events associated with suicidality in patients 
randomised to metyrapone. The estimated impact of metyrapone on suicidality score 
(as measured by item 10 on the MADRS) was a change of -0.15 (95% CI -0.53 and 
0.24). 
 
Patients randomised to metyrapone were less likely to attend follow-up visits than 
patents randomised to placebo (Figure 4). Fitting a Cox proportional hazards model 
the estimated hazard ratio was 0.57 (95% CI: 0.35, 0.93), however, most of the 
divergence occurred in the period after active treatment ended at week +3. 
 
- Fig 4 near here - 
 
 
Discussion 
The key finding of the ADD study is that in a UK NHS population mainly of out-patients 
with TRD in primary or secondary care, augmentation of serotonergic antidepressants 
with metyrapone is ineffective. This result remained unchanged when only data from 
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patients with clear evidence of adherence to study medication were included in the 
analysis. A lack of effect was also seen on all secondary outcome measures.   
 
The absence of a clinical response may arguably be consequent on the absence of a 
cortisol response to metyrapone. However in the smaller positive study by Jahn and 
colleagues, cortisol levels were similarly unaffected8 and a previous study has also 
shown a lack of correlation between change in cortisol concentrations and 
improvement in mood with metyrapone.30 The lack of change in cortisol following 
metyrapone treatment may be due to homeostatic mechanisms acting to maintain 
cortisol concentrations by increasing HPA axis drive. In the study by Jahn and 
colleagues, ACTH and 11-deoxycortisol concentrations were robustly increased after 
metyrapone treatment.8 We did not measure ACTH, but 11-deoxycortisol 
concentrations were similarly affected by metyrapone in this study.  
 
It can also be conjectured that the relatively normal baseline HPA axis function in our 
sample may have militated against a clinical response to metyrapone. Our group has 
previously shown that the extent of HPA axis dysregulation predicts clinical response 
to a different anti-glucocorticoid treatment in bipolar depression.31 However, counter 
to this, translational studies from our group show that anti-glucocorticoid strategies 
engender an increase in the prefrontal cortex serotonin response to a selective 
serotonin reuptake inhibitor (SSRI), even in rats with normal HPA axis function.32 In 
the current study, while patients had a small but significantly increased 11pm cortisol 
concentration compared to matched HVs, there was no difference in CAR AUCg or 
AUCi. These AUC measures have been argued to represent total cortisol output and 
the degree to which the HPA axis can activate20 and hence reflect HPA axis function 
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better than a single salivary cortisol concentration. Either way, change in MADRS 
score in patients treated with metyrapone did not relate significantly to baseline HPA 
axis function, or to measures of change in HPA axis function following treatment with 
metyrapone. It is however important to note that our study was not sufficiently powered 
to show whether metyrapone is efficacious in the sub-sample of hypercortisolaemic 
TRD patients. 
 
The ADD Study is the largest RCT of metyrapone augmentation for TRD conducted 
to date. A strength of the current study is that, given the broad inclusion criteria and 
minimal exclusion criteria, it is generalizable to the large numbers of patients in the 
NHS who have TRD. However, there were a large number (n=712; 81%) of exclusions 
between referral and randomisation so we cannot be completely confident that our 
sample is fully representative of the clinical condition in the community at large. 
 
The degree of treatment resistance was assessed using the MGH-TRD staging scale17 
which included taking a treatment history and examination of hospital and GP records. 
We chose a minimum MGH-TRD score of 2 for inclusion which represents a failure to 
respond to at least 2 antidepressants, given usual UK practice in primary care of not 
augmenting or combining medications for depression until after this stage.1 Beyond 
this point there is great divergence in practice in the treatment sequencing for 
individual patients, with patients being referred to secondary care at different stages 
by individual clinicians. The maximum MGH-TRD score for inclusion was set as 10. In 
practice this means 5-6 treatment trials, of at least minimum duration, of different 
antidepressants or strategies allowing for dose optimisation and 
augmentation/combination of drugs in some trials. Use of electroconvulsive therapy 
Page | 21 
 
(ECT) was not an exclusion criterion. However this scores 3 points on the MGH-TRD 
and given that most patients receiving ECT will also have had at least two 
antidepressants (often with dose optimisation and augmentation), few patients treated 
with ECT score under the maximum cut off of 10. Of the 165 patients randomised just 
7 (4%) had received ECT. 
 
This sample in which 45% of patients were from primary care and where the vast 
majority of the 55% from secondary care were outpatients, is very different from that 
in the exclusively inpatient study of metyrapone augmentation of conventional 
antidepressants carried out by Jahn and colleagues.8 The degree of treatment 
resistance is not described for the patients included in the Jahn study.  Given that 
recruitment was on the basis of the patients being acutely unwell and requiring 
admission, it may be that they were less treatment resistant than those in the ADD 
Study, where defined TRD was an inclusion criteria. In addition, the metyrapone group 
in the Jahn study had a slightly higher mean MADRS score at baseline of 31.5 
(SD=7.6) compared with 28.1 (SD=5.5) in the current study. However, the reverse was 
true of baseline BDI scores of 30.0 (SD=8.4) in the Jahn et al. study compared with 
35.6 (SD=10.9) in the current study. High BDI scores and a high BDI/MADRS ratio 
have been associated with poor outcome in TRD.33 Our patients therefore had clinical 
characteristics which are associated with worse outcomes. This is consistent with the 
overall low response and remission rates seen in the current study. These factors may 
explain the differences in findings between those of Jahn et al. and those of the current 
study. 
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There are a number of limitations to consider in relation to the study. Although the trial 
did not reach its original target of 90% power, it achieved 84% power with regards to 
the primary outcome measure. In the binary outcomes of response and remission, the 
very wide confidence interval suggests that the study is not adequately powered to 
detect differences in these measures of outcome, although response and remission 
rates were almost identical in the two groups. The 95% confidence intervals of the 
differences in MADRS scores between groups indicate that it is not possible to exclude 
an advantage to metyrapone of 3.5 points (or a disadvantage of 2.5 points). Therefore, 
while this study does not support the efficacy of metyrapone it cannot exclude a small 
effect (3.5 points comprising an effect size of 0.3). However, the post-hoc analysis 
which included only those patients defined as adherent to treatment supports the 
interpretation that metyrapone lacks efficacy in this population. This analysis is based 
on week +1 endocrine data and so it is possible that some patients who were adherent 
to metyrapone up to that point did not remain so for the subsequent 2 weeks of 
treatment. No assessment of the extent of adherence in the placebo group was 
conducted. The attrition rate in the follow up phase was somewhat higher in the 
metyrapone group than in the placebo group but it is unlikely that this would have 
significantly impacted on the primary clinical outcome measure since the difference in 
attrition was most marked after week +5.  Nevertheless it is important to emphasise 
that the study shows no evidence of efficacy rather than necessarily evidence of no 
efficacy. 
 
The assumption made in the study was that clinical effects on depression would be 
detectable after only 3-weeks treatment with metyrapone. However, apart from the 
Jahn et al study,8 there is no empirical evidence to confirm this and it is not possible 
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to exclude that longer treatment with metyrapone could have had a positive effect. 
However current evidence suggests that antidepressant treatments start to work 
during the first week of treatment and separation between active and placebo arms is 
seen early even though statistical significance may not occur for a number of weeks.34 
There was no indication of this early effect occurring in our study (Figure 3), indeed 
there was less improvement on metyrapone at the end of active treatment, making it 
unlikely that extending treatment would have shown benefit. 
 
The main conclusion is that in the population of depressed patients studied, the 
addition of metyrapone to standard serotonergic antidepressants is not effective and 
therefore cannot be recommended as a treatment option for TRD. A question remains 
as to why the ADD study was negative when an effect of anti-glucocorticoid treatment 
is supported by preclinical data32 and by a previous RCT of metyrapone 
augmentation.8 This may relate to the nature of the patients studied as discussed 
above and/or their relative lack of HPA axis dysfunction. Chronic depression has been 
shown to be associated with normal HPA axis function.35 The initial hypercortisolaemia 
of depression may normalise with time in patients who continue to demonstrate 
symptoms; hence normal cortisol levels may be a consequence or a cause of chronic 
treatment resistant depression. This is an important issue for future research to clarify. 
Additionally, despite significant heterogeneity between different patient subgroups, 
there remains evidence for HPA axis dysfunction in depression.36 HPA axis genes also 
appear to be central to the gene-environment interactions linking well-established 
aetiological factors, such as early life trauma, and the development of depression37, 
as well as the genetic and epigenetic factors underlying the stress-diathesis model of 
depression.38 Therefore there continues to be a need for further exploration of 
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treatments targeting the HPA axis for the prevention and treatment of depression. For 
example, it would be of interest to explore the efficacy of metyrapone augmentation in 
acutely depressed patients, particularly those with demonstrable hypercortisolaemia.   
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Figure and Table Titles and Legends 
Figure 1: Study CONSORT diagram.   
Figure 2: Salivary cortisol concentrations of patients and matched healthy volunteers.  
Data is plotted for salivary cortisol concentrations at 11pm and following awakening. 
The data following awakening is used to calculate the area under the curve (AUCg 
and AUCi) for the cortisol awakening response (CAR). Data represents means with 
standard error bars. 
Figure 3: Montgomery Asberg Depression Rating Scale (MADRS) scores of patients 
randomised to metyrapone or placebo over time.  
Data represents means with standard error bars.  
Figure 4: Patient retention in study over time.  
Kaplan-Meier survival curve for patients randomised to metyrapone (n=83) or placebo 
(n=82) remaining in the study. 
 
Table 1: Patient and healthy volunteer demographic information. 
Table 2: Patient baseline Montgomery Asberg Depression Rating Scale (MADRS) 
scores by site and source (primary versus secondary care). 
Table 3: Response and remission rates at week +5 for patients randomised to 
metyrapone or placebo. 
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Antidepressant augmentation with metyrapone for 
treatment resistant depression (The ADD Study): a 
double-blind, randomised, placebo controlled trial 
McAllister-Williams et al. 
 
Research in context 
Evidence before this study 
There is abundant evidence of abnormalities in hypothalamic-pituitary-adrenal (HPA) axis 
function in at least a proportion of patients with major depression disorder (MDD), with some 
patient cohorts demonstrating hypercortisolaemia.  As a result a number of anti-
glucocorticoid treatments have been investigated in patients with MDD, particularly those 
with treatment resistant depression (TRD).  One such anti-glucocorticoid treatment is 
metyrapone.  To date, one small (n=63) double blind randomised controlled trial of 
metyrapone augmentation of serotonergic antidepressants in German in-patients has been 
described (Search using PubMed with terms “depression” and “metyrapone”; May 2015).  
This found a positive difference 2 weeks after a 3 week course of metyrapone 1g daily, 
compared to placebo, with an effect size of 0.63 for the reduction in Montgomery-Asberg 
Depression Rating Scale (MADRS) score. 
Added value of this study 
The ADD study’s aim was to examine if this demonstrated effect of metyrapone is evident in 
a predominantly out-patient population of patients with TRD recruited using broad inclusion 
criteria in a larger, more naturalistic, sample (n=165).  Further the study aimed to examine 
tolerability and if any beneficial effect seen was sustained over the longer term (6 months).  
As such the study was intended to inform whether metyrapone augmentation was a realistic 
therapeutic option in every-day clinical practice. 
Implications of all the available evidence 
Contrary to the previous double-blind RCT of metyrapone augmentation in TRD, the ADD 
study failed to demonstrate any beneficial effect of metyrapone augmentation.  Treatment, 
however, was well tolerated.  The ADD study therefore suggests that metyrapone 
augmentation of serotonergic antidepressants is not an option for TRD in routine clinical 
practice at this time.  Further research is required to clarify the extent and longitudinal course 
of HPA axis abnormalities in MDD and in TRD, and whether this may help identify 
individuals in whom anti-glucocorticoid treatments may be effective. 
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Fig 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
284 formally screened for 
eligibility  
119 excluded 
 111 not meeting inclusion criteria 
 8 dropped out prior to randomisation 
69 analysed 
14 lost to follow-up: 
 1 withdrew due to side effects 
 1 family bereavement 
 1 admitted due to worsening 
depression and missed assessments 
 1 moved away 
 10 withdrew with no reason stated 
 
83 allocated to metyrapone 82 allocated to placebo 
74 analysed 
8 lost to follow up: 
 6 withdrew with no reason stated 
 2 away on holiday 
Allocation 
Primary 
Outcome  
(week +5) 
165 randomised 
Enrollment 
46 analysed 
23 lost to follow-up: 
 1 withdrew due to side effects 
 1 withdrew to physical health 
concerns 
 1 family bereavement 
 2 admitted for physical health 
problems  
 1 too psychiatrically unwell 
 17 withdrew with no reason stated 
58 analysed 
16 lost to follow-up: 
 1 withdrew to lack of effect 
 1 withdrew due to side effects 
 1 too psychiatrically unwell 
 1 admitted due to physical health 
problems 
 12 withdrew with no reason stated 
End of Follow up 
(week +24) 
877 patients identified / made 
initial contact 
593 not formally screened 
 123 declined to participate  
 294 non response to invite  
 139 ineligible on phone screen  
 37 other reasons  
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Fig 2 
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Fig 3 
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Fig 4 
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Antidepressant augmentation with metyrapone for treatment resistant depression (The 
ADD Study): a double-blind, randomised, placebo controlled trial 
 
McAllister-Williams RH et al. 
 
Supplementary Appendix 
 
The ADD Study Team: Hamid Alhaj1,2, Tanefa Apekey3, Jane Barnes4, Sally Barker2, Samantha Bulmer1,2, 
Stephanie Clutterbuck1, Julie Doughty4, Claire Farrow5, John Gray1, John Hiley6, Allan O. House7, Brett Jones1, 
Sophie Landa1, Anna Massey2, Ella Roelant8, Faye Ryles5, Paul Sigalas1,2, Eleanor Smith1,2, Chris Speed4, Lucy 
Stevens1, Lisa Svennson1, Cathy Symonds9, Helen Watkinson2, Kate Williams9, Sarah Yates1,2. 
 
Affiliations of the ADD Study Team: 
1 - Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK 
2 – Northumberland Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK 
3 - Greater Manchester West Mental Health NHS Foundation Trust 
4 - Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK 
5 – Tees, Esk and Wear Valleys NHS Foundation Trust, UK 
6 – Bradford District Care NHS Foundation Trust, UK 
7 - Institute of Health Sciences, University of Leeds, Leeds, UK 
8 - Leeds and York Partnership NHS Foundation Trust, Leeds, UK 
9 - Neuroscience and Psychiatry Unit, Manchester University, Manchester, UK  
 
 
The ADD Study Statistical Analysis Plan (clinical outcomes only) 
Study objectives  
Primary Clinical Objective: 
 The primary objective is to determine whether metyrapone (500mg twice a day) for 21 days is efficacious 
in augmenting conventional serotonergic antidepressants in TRD in a UK NHS primary and secondary 
care setting.  This is to be assessed by Montgomery-Åsberg Depression Rating Scale (MADRS) scores 
measured two weeks post treatment (week +5 from randomisation), comparing patients treated with 
metyrapone to those treated with placebo. 
Secondary Clinical Objectives:  
1. To determine the clinical effect size at two weeks post-completion of treatment of a three-week 
course of metyrapone (vs placebo) augmentation of antidepressants in depressed patients who have 
failed to respond to at least two courses of antidepressants, in primary care and psychiatric outpatient 
clinics in the UK. 
2. To assess whether the response is sustained for up to 21 weeks post cessation of Metyrapone. 
3. To assess whether metyrapone augmentation improves patients’ quality of life. 
4. To assess the tolerability and safety of metyrapone augmentation in a large sample taken from a 
representative population of psychiatric outpatients and primary care patients with TRD. 
Mechanistic Objectives:  
NOTE:  This version of the Statistical Analysis Plan only includes the mechanistic objectives related to 
the full study sample.  Additional objectives related to sub-samples of patients that had additional 
investigations.  These are referred to in the published protocol (McAllister-Williams et al. BMC 
Psychiatry 2013 Aug 3;13:205) and further details are available on request. 
1. To assess whether metyrapone changes patients’ HPA axis function. 
2. To assess whether changes in HPA axis function are seen 2 weeks after metyrapone treatment. 
3. To assess whether the change in HPA axis function correlates with clinical response. 
4. To assess whether baseline HPA axis function predicts clinical response. 
5. To assess if type and severity of childhood trauma (as assessed by the Childhood Trauma 
Questionnaire (CTQ) scores) predicts clinical response. 
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6. To assess whether the change in, or baseline assessment of, HPA axis function has specific genetic 
underpinning and whether this relates to, or explains better, the clinical response.  
 
Study design: 
Patient randomised double blind randomised controlled parallel trial with half the patients receiving Metyrapone 
and half the patients receiving a placebo. 
Sample size 
Two groups of 85 patients give 90% power to detect an effect size of 0.5 assuming a type 1 error rate of 5%. 
Allowing for 10% attrition during the trial, 95 per group would need to be randomised; 190 in total aged 18-65 
years. 55 healthy control subjects, aged 18-55 with no personal or family history of mental illness are included. 
The target number in the patient group was amended following a delay in starting recruitment and a slow early 
rate of recruitment, following agreement from the Data Monitoring and Ethics Committee (DMEC), the funder 
and the sponsor.  A reduced power of 80% was agreed.  Using the same assumptions as above, and allowing for 
10% attrition prior to the primary outcome measure, the aim was to randomise 70 per group; 140 in total. 
Study population 
This is more fully defined in the ADD study protocol publication.  Patients included had to meet criteria including 
i) having a DSM-IV confirmed diagnosis of a major depressive episode; ii) current symptoms of moderate to 
severe severity as defined by Hamilton Depression Rating Scale -17 item (HDRS17) score of ≥ 18 at week -2 and 
0; iii) have TRD as defined by a Massachusetts General Hospital Treatment Resistant Depression (MGH-TRD) 
staging score of 2-10; iv) currently taking a serotonergic antidepressant. 
CONSORT diagram 
The flow of patients through the study will be described with the aid of a CONSORT diagram. 
Characteristics of groups at baseline 
The baseline characteristics of the study population will be summarised for each study group. 
Compliance with medication and withdrawal from study medication 
Adherence to medication will be assessed using measures of 11-deoxycortisol. 
A 95% confidence interval for the relative odds of withdrawing from the two treatment arms will be reported. 
Completeness of data 
The level of missing data will be reported for each of the study measures of outcome.  
General Analysis Considerations 
Unless otherwise stated, all analyses will use two-tailed tests where appropriate with significance level set at 5%.  
Statistical packages used will include SPSS, STATA and R, as well as specialised packages for MRI/EEG analysis 
etc. 
Primary outcome 
The primary outcome will be assessed using an intention to treat analysis (patients allocated to the group to which 
they were randomised regardless of whether they received the treatment). 
Primary analysis 
 The estimated difference between the treatment groups at week 5 adjusting for randomisation strata will 
be estimated using a mixed model. The dependent variable will be MADRS score at week 5. The baseline 
score at week 0 will be included as a covariate.  Differences between centres will be incorporated as a 
random effect; differences between primary and secondary care origin of the patients will be included as 
a fixed effect. (Statistical packages: SPSS, STATA, R). 
Secondary analyses 
 The difference between MADRS at week 5 and MADRS immediately before treatment (week 0) in two 
arms will be compared using an independent sample t-test utilising all patients in the study in an 
intention-to-treat analysis.  
 The impact of missing data due to patients declining to participate in data collection will be assessed 
using joint modelling of “time to withdrawal from data collection” and MADRS scores.  
 In addition to analysing the data using the conventional MADRS score, the above primary and secondary 
analyses will be repeated utilising the addition “atypical” depression items (rating hypersomnia and 
increased appetite).  In this scoring of the MADRS, the highest score from the conventional sleep and 
atypical sleep items, and conventional appetite and atypical appetite items, will be used to calculate the 
total MADRS score. 
 The intention to treat analyses above will be repeated in a “per protocol analysis” excluding patients who 
discontinued treatment during the three week treatment period.  A second “per protocol” definition will 
utilise the 11-deoxycortisol measure of apparent concordance with treatment. 
Secondary Clinical outcomes 
1. In relation to clinical effect size: 
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a. Response (defined as 50% reduction in MADRS) and remission (defined as MADRS ≤ 10) rates 
at week 5 will be analysed using logistic regression procedures analogous to the mixed models 
described previously.  Variation between centres will be incorporated as a random effect; 
differences between primary and secondary care origin of patients and the difference between 
those randomised to Metyrapone and those randomised to placebo will be included as fixed 
effects. Results will be presented in the form of a 95% confidence interval for the odds of 
response/remission. 
b. In relation to CAS, BDI and STAI measures: 
i. The CAS, BDI and STAI will be analysed by fitting a sequence of nested models. The 
baseline model will include the score at week 5 as the dependent variable, the baseline 
score as a covariate and the difference between study groups as a fixed effect.  
Variation between centres will then be included as a random effect and the difference 
between primary and secondary care origin as a fixed effect. Nested models will be 
compared using a likelihood ratio test. The impact of compliance with treatment will 
be evaluated using the same approach (based on the measures of compliance 
previously defined). Results will be given in the form of unadjusted and adjusted 95% 
confidence intervals for the effect of treatment with Metyrapone. 
2. In relation to whether the response is sustained: 
a. The persistence of change in MADRS, CAS, BDI and STAI scores will be assessed using 
repeated measures ANOVA, adjusting for randomisation strata of centre and primary vs 
secondary care, using all of the data points available. 
b. The speed of response and speed of remission (both defined using MADRS as described above) 
with Metyrapone vs. placebo will be assessed using survival analysis; time to response and time 
to remission will be analysed using a Cox proportional hazards regression model. Results will 
be given in the form of a 95% confidence interval for the hazard ratio between the two groups. 
3. In relation to whether metyrapone improves patient’s quality of life: 
a. The EQ-5D data will be analysed by fitting a sequence of nested models. The baseline model 
will include the score at week 5 as the dependent variable, the baseline score as a covariate and 
the difference between study groups as a fixed effect.  Variation between centres will then be 
included as a random effect and the difference between primary and secondary care origin as a 
fixed effect. Nested models will be compared using a likelihood ratio test. The impact of 
compliance with treatment will be evaluated using the same approach (based on the measures 
of compliance previously defined). Results will be given in the form of unadjusted and adjusted 
95% confidence intervals for the effect of treatment with Metyrapone. 
4. In relation to how well metyrapone is tolerated: 
a. The Toronto Side Effects Scale scores will be analysed utilising data from all patients who had 
at least one dose of study medication.  A second “per protocol” definition will utilise the 11-
deoxycortisol measure of apparent concordance with treatment.   
i. The difference between TSES score at week 3 and TSES score immediately before 
treatment (week 0) in two arms will also be compared using an independent sample t-
test utilising all patients in the study in an intention-to-treat analysis. 
ii. The change in TSES score over time will be compared using a repeated measures 
ANOVA including all available time points. 
iii. Symptoms described by patients will be grouped into clinically relevant clusters and 
analysed.  This will include a specific focus on suicidal and any changes in this during 
or following treatment. 
b. The Young Mania Rating Scale (YMRS) will be analysed in a similar way to that described for 
the TSES. 
Mechanistic Outcomes 
In the full patient sample: 
1. To assess whether metyrapone changes patients’ HPA axis function: 
a. HPA function will be assessed by calculating the Area Under the Curve (AUC) for the CAR 
data, measuring the peak change in cortisol on waking by comparing the initial waking sample 
with the maximum, as well as examining the diurnal change in cortisol using the CAR and the 
11pm saliva sample.  The effect of metyrapone will be compared to placebo in relation to HPA 
axis function at week 3 (end of metyrapone treatment) using ANOVA covarying for the baseline 
at week 0. 
2. To assess whether changes in HPA axis function are seen 2 weeks after metyrapone treatment: 
a. HPA axis function assessed as above comparing data at week 5 covarying for week 0. 
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3. To assess whether the change in HPA axis function correlates with clinical response: 
a. The correlation between change in HPA axis function (CAR AUC and maximal peak, and 
diurnal cortisol, both at week 3 and week 5 compared to week 0) with change in MADRS, CAS, 
BDI, STAI, EQ-5D (week 5 compared to week 0) will be examined. 
4. To assess whether baseline HPA axis function predicts clinical response: 
a. The correlation between HPA axis function (CAR AUC and maximal peak, and diurnal cortisol) 
with change in MADRS, CAS, BDI, STAI, EQ-5D (week 5 compared to week 0) will be 
examined. 
5. To assess if type and severity of childhood trauma (as assessed by the Childhood Trauma 
Questionnaire (CTQ) scores) predicts clinical response: 
a. The correlation between CTQ with change in MADRS, CAS, BDI, STAI, EQ-5D (week 5 
compared to week 0) will be examined. 
6. To assess whether the change in, or baseline assessment of, HPA axis function has specific genetic 
underpinning and whether this relates to, or explains better, the clinical response:  
a. The relationship between clinical response (as described above) and HPA axis function 
compared with a range of candidate polymorphisms will be examined. 
 
Sub group analysis 
The data will be analysed by dividing the sample into those with severe depression (defined as MADRS >30 at 
baseline week 0) or less severe depression.   
Missing data 
Scores for the various scales used will be calculated in accordance with their author’s instructions. In the absence 
of any rule for missing data imputation will be used provided at least half the items in any scale have been 
completed (imputed missing value = mean value of non-missing items).  Missing survival date will be dealt with 
by using the date of censoring and the status of the patient at that point. The secondary outcomes are being 
analysed using mixed models that make use of all data available. The analysis is adjusted to take into account that 
some subjects have provided more information than others. If there is a difference in survival rates we will have 
more “missing” outcome data in one group than another. If this situation occurs the data will be analysed using 
joint modelling as described above. Thus estimates of functional health status and quality of life will be adjusted 
for differences in survival rates. There will be no other data imputation. 
Safety 
The number of serious adverse events in each group will be reported along with a 95% confidence interval for the 
relative odds (between the two treatment groups) of at least one event being reported. 
The number of non-serious adverse events will be compared using a negative binomial regression model. Results 
will be given in the form of a 95% confidence interval for the incidence rate ratio. 
Implementation 
An SAP Implementation Group will be formed to oversee the analysis of all ADD related data.  The analysis of 
the clinical outcomes will be undertaken by the study team based in Newcastle.  The mechanistic and cross 
sectional analyses will be undertaken by various individuals/centres with the agreement of the SAP 
Implementation Group. 
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Glossary of Abbreviations used in the Statistical Analysis Plan 
5-HT  5-hydroxytryptophan, serotonin  
11β -HSD  11β-hydroxysteroid dehydrogenase  
ACTH  Adrenocorticotrophic hormone 
AE Adverse events 
ANT  Attentional Network Test  
AUCg Area Under the Curve Ground  
AUCi Area Under the Curve Increase 
BDI  Beck Depression Inventory  
BFI-44  Big Five Inventory 44  
BOLD Blood-Oxygen Level Dependent 
BSE Between search errors 
CANTAB  Cambridge Neuropsychological Test Automated Battery  
CAR  Cortisol awakening response  
CAS  Clinical Anxiety Scale  
CBT  Cognitive behavioural therapy  
CI  Chief Investigator  
COM Combined memory condition 
CRF  Case report form  
CTA  Clinical trial authorisation  
CTQ  Childhood Trauma Questionnaire  
CTIMP  Clinical trial of an investigational medicinal product  
DHEA  Dehydroepiandrosterone  
DMEC  Data Monitoring and Ethics Committee  
DSM-IV  Diagnostic and Statistical Manual-IV  
ECMT  Emotional Categorization and Memory Test  
EEG  Electroencephalogram  
EEM Emotional enhancement of memory 
EL Emotional labelling 
EM Emotional matching 
EME  Efficacy Mechanism and Evaluation  
ERP  Event related potential  
ESMT  Emotional Source Memory Task  
EQ-5D  EuroQol Quality of Life scale  
FEER  Facial Emotional Expression Recognition  
FEP Facial emotion processing 
fMRI  Functional magnetic resonance imaging  
FWE Family Wise Error 
GCP  Good Clinical Practice  
GR  Glucocorticoid receptors  
GRID-HAMD  GRID Hamilton Depression Rating Scale  
HDRS17  Hamilton Depression Rating Scale – 17 item  
HPA  Hypothalamic-pituitary-adrenal  
HV Healthy volunteers 
HTA  Health technology assessment  
IAPS  International Affective Picture Set  
IMP  Investigational medicinal product  
LDAEP  Loudness dependency of auditory evoked potentials  
LTE  List of Life Threatening Experiences  
LTP  Long term potentiation  
MADRS  Montgomery-Asberg Depression Research Scale  
MCV  Mean cell volume  
MGH  Massachusetts General Hospital  
MHRA  Medicines and Healthcare Regulatory Agency  
MHRN  Mental Health Research Network  
MR  Mineralocorticoid receptors  
MRC  Medical Research Council  
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MTA  Material Transfer Agreement  
NRES  National Research Ethics Service  
NICE  National Institute of Clinical Excellence  
NIHR  National Institute of Health Research  
OLB Object-location binding 
OLM  Object-location memory  
PCRN  Primary Care Research Network  
phMRI Pharmacological functional magnetic resonance imaging 
PI  Principal Investigator  
PIC  Participant Identification Centres  
POM Position-only memory 
QOL  Quality of life  
R & D  Research and Development  
RAVLT  Rey Auditory Verbal Learning Test  
REC  Research Ethics Committee  
ROI Region of Interest 
RRS  Ruminative Responses Scale  
RT Reaction time 
SAE  Serious adverse event  
SARs  Serious adverse reactions  
SM Shape matching 
SmPC  Summary of major product characteristics  
SOP  Standard operating procedure  
SCID  Structured Clinical Interview for DSM  
SCQ  Social Circumstances Questionnaire  
SPM8 Statistical Parametric Mapping 
SSI  Site specific information  
SSRI  Selective serotonin re-uptake inhibitor  
STAI  State Trait Anxiety Inventory  
SUSAR  Suspected unexpected serious adverse reaction  
SWM  Spatial working memory  
TSC  Trial Steering Committee  
TSES  Toronto Side Effects Scale  
VEP Visual Evoked Potential 
WSE Within search errors 
YMRS  Young Mania Rating Scale  
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Supplementary Table 1:  ADD Study assessment schedule 
 
 Enrolment Random
-isation 
Follow up 
Time point Week 
-2 
Week 
0 
Week 
1 
Week 
2 
Week 
3 
Week 
4 
Week 
5 
Week 
8 
Week 
16 
Week 
24 
Assessment of 
eligibility 
√          
Informed 
Consent 
√          
Assessment of 
baseline 
characteristics  
√          
Experimental 
Intervention 
          
Assessment of 
depression 
severity – 
HDRS171 
√ √         
Assessment of 
Clinical 
symptoms – 
MADRS2, 
CAS3, 
BDI4,STAI5, 
YMRS6 
 √   √  √ √ √ √ 
Assessment of 
Quality of Life 
– EQ-5D 
 √   √  √ √ √ √ 
Assessment of 
side effects – 
TSES7 
 √   √  √ √   
Assessment of 
side effects and 
adverse events 
– self report 
 √ √ √ √ √ √ √ √ √ 
Suicide risk 
assessment 
√ √ √  √  √ √ √ √ 
Pregnancy Test 
if indicated 
√ √ √ √ √      
Assessment of 
concomitant 
medication 
√ √ √ √ √ √ √ √ √ √ 
Measurement 
of HPA axis 
function (CAR 
plus 11pm 
saliva sample) 
 √   √  √    
Physical 
observations** 
√***  √    √    
Blood Tests – 
U&E’s, cortisol 
√****  √    √    
 
** - Physical observations comprised sitting and standing pulse and blood, and pressure respiration rate.   
*** - Screening physical observations also included height and weight  
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**** – Screening blood tests also including thyroid function tests, liver function tests and full blood count 
1HDRS17 – Hamilton Depression Rating Scale – 17 item 
2MADRS – Montgomery-Asberg Depression Rating Scale 
3CAS – Clinical Anxiety Scale 
4BDI – Beck Depressive Inventory 
5STAI – State Trait Anxiety Inventory 
6YMRS – Young Mania Rating Scale 
7TSES – Toronto Side Effects Scale 
 
 
Supplementary Table 2: Rates of missing and imputed data 
A – Data at Baseline 
Measure n 
Number of participants at baseline for whom:- 
Mean number of 
imputed items* 
Score is 
missing 
Score has been calculated 
All 
Without 
imputation 
With 
imputation 
MADRS 165 0 165 165 0 - 
CAS 165 0 165 165 0 - 
STAI - State  165 3 162 154 8 1.13 
STAI - Trait  165 3 162 153 9 1.00 
BDI 165 3 162 160 2 6.00 
YMRS 165 1 164 164 0 - 
EQ-5D 165 3 162 162 0 - 
BDI = Beck Depressive Inventory; CAS = Clinical Anxiety Scale EQ-5D = Euroqual 5 dimensions; MADRS 
= Montgomery Asberg Depression Rating Scale; STAI = State Trait Anxiety Inventory 
 
*The mean number of missing items for the subset of participants form whom a total score was calculated 
using imputation.  In the absence of any rule for missing data imputation was used provided at least half the 
items in any scale had been completed.  Imputed missing values were the mean value of non-missing items in 
that scale. 
 
B – Data at primary end point 
Measure n 
Number of participants at primary endpoint for whom:- Mean 
number of 
imputed 
items* 
Score is 
missing 
Score has been calculated 
All 
Without 
imputation With imputation 
MADRS 143 0 143 143 0 - 
CAS 143 0 143 143 0 - 
STAI - State 143 4 139 136 3 2.00 
STAI - Trait 143 4 139 137 2 1.00 
BDI 143 4 139 135 4 3.75 
YMRS 143 0 143 143 0 - 
EQ-5D 143 4 139 139 0 - 
BDI = Beck Depressive Inventory; CAS = Clinical Anxiety Scale EQ-5D = Euroqual 5 dimensions; MADRS = 
Montgomery Asberg Depression Rating Scale; STAI = State Trait Anxiety Inventory 
 
*The mean number of missing items for the subset of participants form whom a total score was calculated using 
imputation (see Table 2A for details). 
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Supplementary Table 3:  Effect of metyrapone on Montgomery Asberg Depression Rating Scale (MADRS) 
scores at week +5 covarying for illness severity, study centre and source of patients (primary versus secondary 
care) on Montgomery Asberg Depression Rating Scale (MADRS) scores at week +5 
 
Included covariates when 
estimating the impact of 
metyrapone on MADRS scores 
five weeks post randomisation 
Regression coefficient Significance 
B 95% CI t p 
None[1] -0.68 -4.23 2.87 -0.38 0.705 
Baseline severity -0.43 -3.45 2.63 -0.28 0.783 
Baseline severity, primary v 
secondary care -0.51 -3.55 2.53 -0.33 0.740 
Baseline severity, centre[2] -0.34 -3.39 2.70 -0.22 0.824 
Baseline severity, primary v 
secondary care, centre[2] -0.43 -3.47 2.61 -0.28 0.782 
Baseline severity, primary v 
secondary care, centre[3][4] -0.51 -3.48 2.46 -0.34 0.736 
Baseline severity, centre[2], 
primary v secondary care, 
compliance with medication[5] -1.65 -4.94 1.65 -0.99 0.33 
[1] analysis of depression score five weeks post randomisation only 
[2] differences between centres fitted as fixed effects 
[3] differences between centres fitted as a random effect 
[4] pre-specified primary analysis 
[5] per protocol analysis (non-compliers omitted from analysis) 
 
 
Supplementary Table 4:  Effect of metyrapone on Montgomery Asberg Depression Rating Scale (MADRS) 
scores at week +5 covarying for HPA axis variables. 
 
Included covariates when 
estimating the impact of 
metyrapone on MADRS scores 
five weeks post randomisation 
Regression coefficient Significance 
B 95% CI t p 
Baseline 11pm cortisol -0.70 -4.63 3.23 -0.35 0.725 
Baseline CAR AUCg -0.56 -4.37 3.25 -0.29 0.771 
Baseline CAR AUCi -0.56 -4.37 3.25 -0.29 0.771 
Baseline to week +5 change in 11 
pm cortisol -1.51 -5.61 2.60 -0.73 0.468 
Baseline to week +5 change in 
AUCg -1.16 -5.22 2.90 -0.56 0.573 
Baseline to week +5 change in 
AUCi -1.13 -5.17 2.92 -0.55 0.582 
NB – for comparison with the primary outcome covariate analysis see supplementary table 3. 
 
AUCg – Area under the curve with respect to zero; AUCi – Area under the curve with respect 
to cortisol concentration on waking; CAR – Cortisol awakening response 
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Persistence of change in MADRS scores 
For each individual, the MADRS score was recorded on up to five occasions following randomisation. These 
repeated measures were analysed using a mixed model in which we assume that for each patient the MADRS 
scores varied randomly about an individual mean score (with standard deviation e) but that this mean varied 
randomly across patients (with standard deviation u). A normal distribution was assumed for each of the 
random effects. Fitting an initial model with only a constant term (corresponding to the assumption that the 
mean MADRS score is the same at all five follow up visits) in addition to the random effects, the estimated 
mean MADRS score across the five follow up visits was 21.6 with 95% CI: 20.1, 23.0. There was significant 
variation of scores both within patients (e= 6.57 with 95% CI: 6.17, 6.99) and between patients (u= 8.58 with 
95% CI: 7.54, 9.78). 
Since we are interested primarily in changes in depression the second step was to include the baseline MADRS 
score as a covariate. This model indicated a significant reduction in depression from baseline at each of the five 
follow up visits. Baseline depression explained some of the variation between individual patients (the estimate 
of u fell to 6.69) but there were still significant differences between patients.  
Adding in differences between randomisation strata (sites and origin of patient-either primary or secondary care) 
did not explain very much additional variability. With the baseline score as a covariate there were no significant 
differences between these strata. The estimated difference in depression across all five follow up visits between 
patients on metyrapone and patients on placebo was 0.75 with 95% CI (-1.59, 3.10). 
There was no evidence of any trend in depression over the follow up visits. Adding a linear trend over visits to 
the model the estimated mean change in MADRS score between consecutive visits was 0.27 (95% CI:   0.65, 
0.10) and did not constitute a clinically important change in depression.  
Supplementary Table 5:  Means and standard deviations of all clinical outcome measures 
  Metyrapone Placebo 
  Base-
line 
Wk 
+3 
Wk 
+5 
Wk 
+8 
Wk 
+16 
Wk 
+24 
Base-
line 
Wk 
+3 
Wk 
+5 
Wk 
+8 
Wk 
+16 
Wk 
+24 
 
MADRS 
Mean 27.7 22.6 21.71 21.2 21.4 21.0 28.1 20.8 22.4 22.6 20.5 20.0 
SD 6.7 10.9 10.9 10.4 11.0 11.1 5.5 9.9 10.6 10.8 11.5 11.6 
n 83 72 69 62 54 46 82 77 74 66 61 58 
 
BDI 
Mean 35.6 30.5 27.9 28.7 30.5 28.2 34.8 28.7 29.6 30.9 28 28.9 
SD 10.9 15.1 15.3 14.9 14.2 14.2 10.3 14 14.5 14.4 15.7 16.9 
n 81 69 67 61 52 47 81 75 72 63 61 57 
 
CAS 
Mean 9.5 8.5 8.5 8.7 8.5 7.9 10.0 7.4 8.2 8.5 7.7 7.4 
SD 4.5 6.2 6.0 6.0 5.0 5.7 4.6 5.2 5.8 5.6 4.9 5.3 
n 83 72 69 62 54 46 82 77 74 66 61 58 
 
EQ-5D 
Mean 0.37 0.44 0.50 0.47 0.49 0.49 0.37 0.46 0.47 0.45 0.45 0.44 
SD 0.30 0.33 0.35 0.34 0.33 0.35 0.31 0.33 0.35 0.36 0.36 0.37 
n 81 69 67 60 52 47 81 75 72 64 60 58 
 
EQ-
VAS 
Mean 40.9 48.4 50.6 49.4 48.2 48.3 42.3 47.3 47.5 49.4 47 47.4 
SD 16.6 20.8 21.9 20.0 20.0 19.7 19.4 20.8 22.1 22.0 23.9 25.0 
n 80 65 63 59 51 47 79 74 71 64 61 58 
 
YMRS 
Mean 2.3 2.0 1.7 1.6 1.9 1.5 2.4 1.9 1.7 1.7 1.7 1.8 
SD 1.7 1.7 1.6 1.7 1.9 1.8 1.8 2.2 1.9 1.9 2.1 2.1 
n 82 72 69 62 54 46 82 77 74 66 61 59 
 
STAI - 
State 
Mean 42.8 42.9 42.1 41.3 42.3 42.4 41.1 39.9 40.3 40.7 41.2 41.3 
SD 6.5 7.1 6.9 7.2 6.1 6.1 5.8 5.5 6.0 7.0 7.3 6.2 
n 81 69 67 59 52 47 81 75 72 64 58 56 
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BDI – Beck Depressive Inventory; CAS – Clinical Anxiety Scale; EQ-5D – European Quality of Life-5 
Dimensions; EQ-VAS – European Quality of Life Visual Analogue Scale; MDRS – Montgomery Asberg 
Rating Scale; SD – Standard Deviation; STAI – State Trait Anxiety Inventory; YMRS – Young Mania Rating 
Scale 
 
 
Supplementary Table 6:  Serious adverse effects 
 
Event description Treatment 
allocation 
Breast cancer (diagnosis preceded 
randomisation), dehydration/leucopenia 
Placebo 
Groin infection/abscess Placebo 
Overdose  (tramadol, pregabalin, 
amitryptiline and alcohol) 
Metyrapone 
Migraine with medication overuse 
headaches, right Holmes-Adie pupil 
Metyrapone 
Increased suicidal thoughts Placebo 
Dislocated knee/broken leg (bike accident) Placebo 
Overactive bladder Metyrapone 
Mood deterioration Metyrapone 
Patient took unknown amount of ketamine Placebo 
Increase in symptoms of depressed mood 
and re-emergence of suicidal ideation 
Placebo 
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Supplementary Table 7: Side effect incidence on Toronto Side Effect Scale (TSES) 
Side Effect 
Incidence Frequency Severity 
Metyrapone Placebo Metyrapone/Placebo Metyrapone Placebo Metyrapone Placebo 
n % n % RR 95%CI  95%CI  95%CI  95%CI  95%CI 
Nervousness  53 77 53 72 1.1 0.9 1.3 2.9 2.5 3.3 2.5 2.2 2.8 2.6 2.3 2.9 2.4 2.1 2.7 
Agitation  55 80 52 70 1.1 0.9 1.4 3.1 2.7 3.5 2.6 2.3 3.0 2.8 2.4 3.1 2.5 2.2 2.8 
Tremor  28 41 21 28 1.4 0.9 2.3 1.9 1.5 2.2 1.6 1.4 1.9 1.7 1.4 2.0 1.5 1.2 1.7 
Myoclonus  25 36 32 43 0.8 0.6 1.3 1.9 1.6 2.3 1.9 1.6 2.2 1.6 1.4 1.9 1.6 1.4 1.8 
Abdominal pain 23 33 27 36 0.91 0.58 1.43 1.68 1.40 1.97 1.82 1.51 2.14 1.74 1.45 2.02 1.81 1.50 2.13 
Dyspepsia 27 40 32 43 0.92 0.62 1.36 1.74 1.46 2.01 1.76 1.49 2.02 1.68 1.43 1.92 1.80 1.51 2.08 
Nausea 27 39 29 39 1.00 0.66 1.50 1.68 1.43 1.94 1.62 1.39 1.85 1.81 1.51 2.11 1.66 1.42 1.91 
Diarrhoea 21 30 26 35 0.87 0.54 1.39 1.52 1.29 1.75 1.59 1.35 1.84 1.54 1.31 1.76 1.62 1.36 1.88 
Constipation 23 33 29 39 0.85 0.55 1.32 1.72 1.43 2.02 1.96 1.64 2.28 1.57 1.32 1.81 1.80 1.50 2.09 
Decreased appetite 34 49 47 64 0.78 0.58 1.04 2.52 2.11 2.94 2.91 2.50 3.31 1.93 1.59 2.27 2.03 1.69 2.36 
Increased appetite 16 30 19 26 0.90 0.51 1.61 1.48 1.22 1.73 1.50 1.26 1.74 1.29 1.10 1.48 1.38 1.15 1.60 
Weakness or fatigue 56 80 61 82 1.0 0.8 1.2 3.6 3.2 4.0 3.6 3.3 4.0 3.1 2.8 3.5 3.5 3.1 3.8 
Dizziness 24 53 25 34 1.0 0.7 1.6 1.7 1.4 2.0 1.7 1.4 1.9 1.7 1.4 2.0 1.7 1.4 1.9 
Postural hypotension 25 36 32 43 0.8 0.6 1.3 1.6 1.4 1.8 2.0 1.7 2.3 1.6 1.4 1.90 1.7 1.4 2.0 
Drowsiness 48 70 55 74 0.9 0.8 1.2 2.9 2.5 3.3 2.8 2.5 3.2 2.6 2.2 3.0 2.5 2.2 2.8 
Increased sleep 15 22 18 24 0.9 0.5 1.6 1.5 1.2 1.8 1.6 1.3 1.9 1.3 1.1 1.6 1.4 1.2 1.7 
Decreased sleep 46 67 55 74 0.90 0.72 1.11 3.09 2.67 3.51 3.09 2.71 3.47 2.90 2.48 3.31 2.85 2.48 3.22 
Sweating 39 56 43 58 0.97 0.73 1.29 2.20 1.87 2.54 2.27 1.94 2.60 2.13 1.81 2.45 2.11 1.80 2.42 
Flushing 31 45 29 39 1.15 0.78 1.69 2.00 1.67 2.33 1.73 1.47 1.99 1.81 1.52 2.10 1.70 1.42 1.98 
Oedema 17 25 17 23 1.07 0.60 1.93 1.72 1.38 2.07 1.57 1.29 1.84 1.48 1.22 1.73 1.50 1.25 1.75 
Headache 47 68 57 77 0.88 0.72 1.08 2.35 2.03 2.66 2.68 2.36 2.99 2.26 1.95 2.57 2.55 2.25 2.86 
Blurred vision 23 33 22 30 1.12 0.69 1.82 1.67 1.39 1.95 1.62 1.35 1.89 1.54 1.30 1.77 1.49 1.27 1.70 
Dry mouth 47 68 54 73 0.93 0.75 1.15 3.16 2.73 3.59 3.03 2.62 3.43 2.59 2.20 2.98 2.30 1.95 2.64 
Anorgasmia 39 57 42 57 1.00 0.75 1.33 2.91 2.46 3.37 2.84 2.41 3.26 1.46 1.19 1.74 1.57 1.28 1.85 
Increased libido 4 6 6 8 0.71 0.21 2.43 1.09 1.00 1.18 1.12 1.00 1.24 1.17 1.04 1.31 1.12 0.97 1.27 
Decreased libido 33 48 37 50 0.96 0.68 1.34 2.71 2.25 3.17 2.66 2.23 3.09 1.84 1.50 2.18 1.74 1.43 2.05 
Premat. ejaculation 1 3 1 3 1.00 0.07 15.28 1.13 0.87 1.39 1.03 0.97 1.10 1.13 0.87 1.39 1.00 - - 
Delayed ejaculation 1 3 8 27 0.12 0.02 0.91 1.13 0.87 1.39 1.60 1.18 2.02 1.13 0.87 1.39 1.48 1.08 1.88 
Erectile dysfunction 9 29 8 27 1.09 0.48 2.45 2.13 1.47 2.79 1.93 1.31 2.55 1.39 0.95 1.83 1.43 1.02 1.85 
Other, specify 0 0 0 0 - - - 1.00     1.00 - - 1.00 - - 1.00 - - 
Weight gain 20 29 15 20 1.43 0.80 2.56 1.64 1.34 1.93 1.43 1.20 1.67 1.51 1.24 1.77 1.43 1.18 1.68 
Weight loss 7 10 18 25 0.41 0.18 0.92 1.14 1.03 1.26 1.47 1.24 1.69 1.07 0.97 1.18 1.04 0.99 1.09 
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Effect of metyrapone on BDI scores 5 weeks post randomisation 
As defined in the Statistical Analysis Plan, scores obtained five weeks post randomisation were analysed using 
analysis of covariance with baseline scores included as a covariate. This suggested a difference of -2.65 (95% CI: 
-6.53, 1.23) between the effects of metyrapone and placebo. Adjusting for random variation between centres and 
a difference between patients originating from primary and secondary care gave an adjusted estimate of -2.65 
(95% CI:  6.41, 1.10) that was not significantly different from zero. 
 
Supplementary Figure 1: Beck Depressive Inventory (BDI) scores of patients randomised to metyrapone or 
placebo over time.  Data represents means with standard error bars. 
 
 
 
 
Effect of metyrapone on CAS scores 5 weeks post randomisation 
Based on analysis of covariance of CAS scores recorded 5 weeks post randomisation (with baseline scores 
included as a covariate) the unadjusted estimate of the effect of metyrapone was 0.55 (95% CI: -1.21, 2.30). 
Adjusting for differences between centres and patient origin of care the estimated effect of metyrapone on CAS 
scores was 0.46, (95% CI: -1.20, 2.12). These estimates correspond to differences between groups that are neither 
statistically nor clinically significant. 
 
Supplementary Figure 2: Clinical anxiety Scale (CAS) scores of patients randomised to metyrapone or placebo 
over time.  Data represents means with standard error bars. 
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Effect of metyrapone on EQ-5D-3L health tariffs 5 weeks post randomisation 
Based on a simple analysis of covariance model with baseline EQ-5D-3L value included as a covariate, the 
estimated effect of metyrapone was a change in EQ-5D-3L value of 0.014 (95% CI: -0.073, 0.101). Adjusting for 
variation between sites and origin of patient care the estimated effect of metyrapone was 0.015 (95% CI: -0.069, 
0.099). There was no evidence of a beneficial effect of treatment with metyrapone on EQ-5D-3L. 
 
Supplementary Figure 3: EuroQoL (EQ-5D-3L) scores of patients randomised to metyrapone or placebo over 
time.  Data represents means with standard error bars. 
 
 
 
Effect of metyrapone on EQ-VAS at 5 weeks post randomisation 
The estimated effect of metyrapone at five weeks post randomisation (analysis of covariance with baseline scores 
included as a covariate) was 5.7 (95% CI: -0.8, 12.1). Adjusting for origin of patient and variation between centres 
the adjusted estimate is 5.6 (95% CI: -0.7, 12.0). 
 
Supplementary Figure 4: EuroQoL visual analogue scale (EQ-VAS) scores of patients randomised to 
metyrapone or placebo over time.  Data represents means with standard error bars. 
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The effect of metyrapone on YMRS scores 
Mean and standard deviation YRMS scores for each randomised group are reported for all visits (see 
Supplementary figure 5). The estimated difference between patients randomised to metyrapone and placebo at 
five weeks post randomisation (analysis of covariance of week 5 scores with baseline scores included as a 
covariate) was -0.04 (95% CI: -0.54, 0.46). Adjusting for origin of patient and variation between centres resulted 
in almost no change to the estimate; the adjusted estimate is -0.04 (95% CI: -0.52, 0.45). There is no evidence of 
different levels of manic symptoms between patients randomised to metyrapone and placebo. 
 
Supplementary Figure 5: Young Mania Rating Scale (YMRS) scores of patients randomised to metyrapone or 
placebo over time.  Data represents means with standard error bars. 
 
 
 
Effect of metyrapone on state anxiety scores 5 weeks post randomisation 
Based on an analysis of covariance the estimated effect of metyrapone relative to placebo at week 5 was an 
increase in state anxiety of 1.2 (95% CI: -0.7, 3.1). This is consistent with the larger fall in in anxiety between 
baseline and week 5 in the group randomised to metyrapone than in the other group that can be seen in 
supplementary figure 6. However the difference between groups is not statistically significant (p = 0.21). 
Adjusting for origin of patient care and differences between centres resulted in very little change in the estimated 
impact; adjusted estimate was an increase in anxiety of 1.2 (95% CI: -0.6, 3.0). 
 
Supplementary Figure 6: State Trait Anxiety Inventory (STAI) - state scores of patients randomised to 
metyrapone or placebo over time.  Data represents means with standard error bars. 
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